Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCETRIS post-marketing all-case surveillance in relapsed or refractory CD30+ Hodgkin lymphoma or anaplastic large cell lymphoma
jRCT1080222405
- Sponsor
- Takeda
- Start
- Feb 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by Takeda.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on jRCT1080222405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222405.